Research Article

Enhanced active efflux, repression of porin synthesis and development of Mar phenotype by diazepam in two enterobacteria strains

Journal of Medical Microbiology 2004; 53(11):1119 · https://doi.org/10.1099/jmm.0.45613-0

View at publisher PubMed

Abstract

Previous works have reported an impaired immune response and decreased survival to bacterial infections as side-effects of treatment with diazepam, both in humans and in mice (Covelli et al., 1991; Galdiero et al., 1995; Laschi et al., 1983). Nevertheless, diazepam has not yet been evaluated as an inducer of bacterial antibiotic resistance. The possibility that diazepam might induce the Mar phenotype in addition to an impaired immune response would increase the risk of refractory infections to antimicrobial treatments. In this study, we compared the behaviour of diazepam with that of salicylate or benzoate as inducers of multiple antibiotic resistance in two strains of both K. pneumoniae and E. coli.

Several chemicals, such as sodium salicylate (salicylate) and sodium benzoate (benzoate) and chemotherapeutic agents, such as clofibric and ethacrynic acids (Alekshun & Levy, 1997; Balagué & Véscovi, 2001) induce a multiple antibiotic resistance phenotype (Mar) in Escherichia coli by the activation of the marRAB operon. This activation increases MarA expression (transcriptional activator of mar regulon) resulting in a Mar phenotype that is characterized by decreased susceptibility to multiple antibiotics due to increased active efflux and decreased expression of OmpF (Alekshun & Levy, 1997). RamA is another transcriptional activator, a MarA homologue (Alekshun & Levy, 1997) that has been identified in multidrug-resistant mutants of Klebsiella pneumoniae (George et al., 1995). Thus, we were interested in identifying other chemotherapeutic agents that may also induce Mar phenotype.

Previous works have reported an impaired immune response and decreased survival to bacterial infections as side-effects of treatment with diazepam, both in humans and in mice (Covelli et al., 1991; Galdiero et al., 1995; Laschi et al., 1983). Nevertheless, diazepam has not yet been evaluated as an inducer of bacterial antibiotic resistance. The possibility that diazepam might induce the Mar phenotype in addition to an impaired immune response would increase the risk of refractory infections to antimicrobial treatments. In this study, we compared the behaviour of diazepam with that of salicylate or benzoate as inducers of multiple antibiotic resistance in two strains of both K. pneumoniae and E. coli.

Bacterial strains and drugs.
The effects of salicylate, benzoate and diazepam were studied in a clinical isolate of K. pneumoniae (KP1A02) and in the wild-type E. coli strain Ag100. K. pneumoniae ATCC 10031 (donated by Dr Federico Uruburu, Spanish Type Culture Collection, Valencia, Spain) and strain Ag112 were used as control strains. Strain Ag112 (an OmpF-deficient strain) is a marR mutant derived from strain Ag100 (Oethinger et al., 2000). Strains Ag100 and Ag112 were donated by Dr S. B. Levy, Tufts University School of Medicine, Boston, USA.

Salicylate, benzoate and antimicrobial agents were purchased from Sigma. Diazepam was purchased from Roche. An agar dilution method following NCCLS guidelines was used in the susceptibility tests (NCCLS, 2003a).

Preparation and analysis of outer-membrane proteins (OMPs).
Bacterial cell pellets were obtained from 1 l of mid-exponential-phase cultures grown in antibiotic medium no. 3 (Difco) with or without diazepam (0.0150.5 mM) and salicylate or benzoate (0.2520 mM). Bacterial cells were disrupted by sonication, separating unbroken cells from cell envelopes by centrifugation. A 2 % sodium lauroyl sarcosinate solution was used to solubilize cytoplasmic membranes, leaving insoluble outer membranes, which were recovered by centrifugation as a pellet. Each membrane suspension (10 µg) in loading buffer was electrophoresed by SDS-PAGE (Tavío et al., 1999).

Measurements of norfloxacin accumulation.
Norfloxacin intracellular accumulation was measured as previously described (Tavío et al., 1999). The norfloxacin uptake measurements were simultaneously performed in strains KP1A02 and Ag100 grown with and without subinhibitory concentrations of diazepam (0.030.5 mM) and salicylate or benzoate (520 mM). Salicylate and benzoate MICs were 20 mM in strain Ag100 and 40 mM in strain KP1A02. Diazepam MICs were 0.5 mM in strain Ag100 and 1 mM in strain KP1A02. Likewise, all the above were assayed with and without the presence of 50 and 100 µM carbonyl cyanide m-chlorophenylhydrazone (CCCP), an inhibitor of proton motive force (Oethinger et al., 2000; Alekshun & Levy, 1997). Norfloxacin concentration in each cellular extract was measured at least six times by bioassay using K. pneumoniae ATCC 10031, as previously described (Tavío et al., 1999). K. pneumoniae ATCC 10031 is recommended by Spanish Type Culture Collection for susceptibility tests. Norfloxacin intracellular concentration in extracts was determined by a disk-diffusion method (NCCLS, 2003b). The inhibition zones produced by 20 µl aliquots of each extract were compared with those produced by 20 µl aliquots of different known norfloxacin concentrations using non-linear regression. The accepted standard deviation for all the norfloxacin uptake results was always 5 % with respect to each mean value of the three measurements that were taken at 5, 10, 15 and 20 min, with and without CCCP.

The norfloxacin uptake basal level was defined as intracellular norfloxacin concentration in the strains grown without salicylate, benzoate, diazepam or CCCP.

Several drugs have been identified as inducers of the Mar phenotype in E. coli by the activation of the marRAB operon (Alekshun & Levy, 1997; Balagué & Vescovi, 2001). Diazepam is not among the chemotherapeutic agents analysed as potential inducers of the Mar phenotype despite its frequent use by clinicians. Different studies have attributed a decreased survival to bacterial infections (Galdiero et al., 1995), such as those caused by K. pneumoniae (Laschi et al., 1983), to diazepam. Therefore, it would be particularly interesting to find out whether diazepam may also be an inducer of the Mar phenotype in a K. pneumoniae clinical isolate by comparing the results with those in an E. coli wild-type strain.

OMP analyses showed the loss of both 36 and 34 kDa OMPs in the KP1A02 strain induced by 0.5 mM diazepam and 20 mM salicylate or benzoate (Fig. 1a). Likewise, diazepam, salicylate and benzoate increased the expression of a 42 kDa OMP (Fig. 1a), although 0.03 mM diazepam did not induce any changes in the OMPs of the KP1A02 strain. By contrast, 0.030.25 mM diazepam repressed OmpF expression in strain Ag100, leading to the same OMP profile as E. coli strain Ag112 (Fig. 1c), matching the effect of benzoate (Fig. 1b) and coinciding with previous descriptions (Alekshun & Levy, 1997). Diazepam concentrations 0.015 mM were not assayed more extensively since they did not induce OMP changes in either of these two strains.



(77K):

Fig. 1. (a) SDS-11 % PAGE of OMPs prepared from the following strains: 1, KP1A02; 2, KP1A02 in 20 mM sodium benzoate (SB); 3, KP1A02 in 10 mM SB; 4, KP1A02 in 5 mM SB; 5, KP1A02 in 0.5 mM diazepam (DZ); 6, KP1A02 in 0.25 mM DZ; 7, KP1A02 in 0.12 mM DZ; 8, KP1A02 in 20 mM sodium salicylate (SL); 9, KP1A02 in 10 mM SL; 10, KP1A02 in 5 mM SL; 11, K. pneumoniae ATCC 10031; 12, Molecular mass standards corresponding to ovalbumin (45 kDa), glyceraldehyde-3-phosphate dehydrogenase (36 kDa), carbonic anhydrase (29 kDa). The 42 kDa OMP is marked by →, the 34 kDa OMP by ". (b) 6 M Urea SDS-10 % PAGE of OMPs prepared from the following strains: 1, E. coli Ag100 in 10 mM SB; 2, E. coli Ag100 in 5 mM SB; 3, E. coli Ag100 in 0.5 mM SB; 4, E. coli Ag100 in 0.25 mM SB; 5, E. coli Ag112; 6, E. coli Ag100. (c) 6 M Urea SDS-10 % PAGE of OMPs prepared from the following strains: 1, E. coli Ag100; 2, E. coli Ag112; 3, E. coli Ag100 in 0.25 mM DZ; 4, E. coli Ag100 in 0.12 mM DZ; 5, E. coli Ag100 in 0.03 mM DZ (); 6, E. coli Ag100 in 0.015 DZ. C, OmpC; F, OmpF; A, OmpA.

For the susceptibility tests, all the assayed diazepam concentrations increased MICs to ß-lactams, quinolones, tetracycline and chloramphenicol in both the KP1A02 and Ag100 strains, similar to the effect of salicylate or benzoate (Table 1). In line with these results, the Mar phenotype in E. coli (or its equivalent in K. pneumoniae) is characterized by increased MICs of antibiotics that cross the outer membrane preferentially through porins and/or which are efflux pump substrates, such as ß-lactams, nalidixic acid, norfloxacin, tetracycline and chloramphenicol (Alekshun & Levy, 1997; Doménech-Sánchez et al., 2003). Mar phenotypes induced by diazepam, salicylate and benzoate did not always result in MICs the breakpoints for assayed antibiotics. Thus, norfloxacin MICs were 2 µg ml1, as in strains that show decreased permeability in the outer membrane and enhanced active efflux to fluoroquinolones (Martínez-Martínez et al., 2002; Kern et al., 2000). In this way, MICs of the antimicrobial agents assayed in strain Ag100 grown with diazepam, salicylate or benzoate matched in many cases those found in strain Ag112 (a Mar phenotype strain) (Oethinger et al., 2000) grown without the presence of any of these chemicals (Table 1).


Table 1. Effect of salicylate, diazepam and benzoate on antimicrobial agents MICs (µg ml1) FOX, cefoxitin; CP, cephalothin; TE, tetracycline; CL, chloramphenicol; NA, nalidixic acid; NOR, norfloxacin; ND, not done.


Thus, changes in OMP expression and development of the Mar phenotype were induced by some of the standard clinical doses of diazepam, bearing in mind that the usual maximum adult dosage for diazepam is 40 mg day1 in tablets and 160 mg intramuscular or intravenous (Roche dosage recommendations). This means that the normal adult dosage per day could be 0.03 mM or 0.12 mM, although therapeutic doses may sometimes reach 400 mg day1 (0.3 mM).

Changes in norfloxacin uptake were also induced by diazepam, salicylate or benzoate. Norfloxacin uptake levels induced by 20 mM salicylate or benzoate and 0.5 mM diazepam (Table 2) in strain KP1A02 (3.24.1-fold less than the basal level) were characteristic of K. pneumoniae strains that do not express OmpK36 and show enhanced active efflux (Martínez-Martínez et al., 1998). The concomitant 16-fold increase in norfloxacin MICs in strain KP1A02 (Table 1) might be explained by the participation of the above two mechanisms of resistance, as previously described in other strains (Doménech-Sánchez et al., 2003; Schneiders et al., 2003). Likewise, 5 or 10 mM salicylate or benzoate and 0.12 or 0.25 mM diazepam decreased norfloxacin uptake 23.2-fold in strain KP1A02 (Table 2), concomitant with a four to eightfold increase in norfloxacin MIC, probably due to both the decreased expression of 36 kDa OMP (not total loss) and enhanced active efflux, as previously reported (Martínez-Martínez et al., 1998; Doménech-Sánchez et al., 2003). Moreover, diazepam, salicylate or benzoate decreased norfloxacin uptake 310.3-fold in strain Ag100 (Table 2), an effect similar to that which occurs when the mar regulon is activated (Kern et al., 2000; Oethinger et al., 2000) (Table 2). Reduced norfloxacin uptake was concomitant with a two to eightfold increase in norfloxacin MIC, as previously associated with the development of the Mar phenotype in E. coli strains (Oethinger et al., 2000).


Table 2. Effect of salicylate, diazepam and benzoate on norfloxacin uptake by bacterial cells [ng norfloxacin (mg dry cell)1] ND, Not done.


The use of CCCP for evaluating active efflux showed that incubation of strains KP1A02 and Ag100 in 50 or 100 µM CCCP increased the intracellular norfloxacin basal level 1.6-fold (Table 2). This increase is within the range of response to CCCP in susceptible strains (Kern et al., 2000; Oethinger et al., 2000). Earlier studies have confirmed that fluoroquinolone-susceptible E. coli cells use energy to reduce the intracellular level of norfloxacin. In these cases, when proton motive force is dissipated by CCCP, the increase in fluoroquinolone accumulation is twofold the basal level (Oethinger et al., 2000). By contrast, a 2.55.1-fold increase in norfloxacin uptake in strain KP1A02, grown with diazepam, salicylate or benzoate, was induced by 50100 µM CCCP (Table 2). Thus, incubation with CCCP restored or exceeded the intracellular norfloxacin basal level in strain KP1A02. These results agree with previous studies on K. pneumoniae that attribute a main role to active efflux in norfloxacin uptake (Martínez-Martínez et al., 2002; Doménech-Sánchez et al., 2003). Nevertheless, despite a 2.26.3-fold increase in norfloxacin uptake through the effect of 50 or 100 µM CCCP in strain Ag100 grown in salicylate, benzoate and diazepam (Table 2), norfloxacin uptake was always less than the basal level in strain Ag100, concurring with the previously described role of OmpF in outer membrane permeability to norfloxacin in E. coli strains (Kern et al., 2000; Mortimer & Piddock, 1993).

In conclusion, diazepam effects on outer-membrane protein expression, active efflux and antimicrobial agent MICs in strains KP1A02 and Ag100 matched to a notable extent those induced by two recognized marRAB inducers (salicylate and benzoate) (Alekshun & Levy, 1997). The above results suggest that diazepam concentrations equal or twice adult dosage might induce the expression of MarA in E. coli strains or RamA in K. pneumoniae strains (George et al., 1995; Schneiders et al., 2003). Thus, diazepam might play a role not only as a cause of impaired immunity to bacterial infections as previously described by Laschi et al. (1983), but also as an inducer of the bacterial Mar phenotype. The conjunction of both mechanisms induced by diazepam might lead to a refractory infection. Therefore, the potential development of the bacterial Mar phenotype in a concomitant infection with a diazepam treatment in humans should not be ruled out.

This work was supported by subsidy 2002/199 awarded by the Canary Government.

References

  • Alekshun, M. N. & Levy, S. B. (1997). Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon. Antimicrob Agents Chemother 41, 20672075.[Medline]
    • Balagué, C. & Vescovi, E. G. (2001). Activation of multiple antibiotic resistance in uropathogenic Escherichia coli strains by aryloxoalcanoic acid compounds. Antimicrob Agents Chemother 45, 18151822.[Abstract/Free Full Text]
    • Covelli, V., Munno, I., Decandia, P., Altamura, M., Cannuscio, B., Maffione, A. B. & Jirillo, E. (1991). Effects of benzodiazepines on the immune system. Acta Neurol (Napoli) 13, 418423.
    • Doménech-Sánchez, A., Martínez-Martínez, L., Hernández-Allés, S., Conejo, M. C., Pascual, A., Tomás, J. M., Alberti, S. & Benedí, V. J. (2003). Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother 47, 33323335.[Abstract/Free Full Text]
    • Galdiero, F., Bentivoglio, C., Nuzzo, I., Ianniello, R., Capasso, C., Mattera, S., Nazzaro, C., Galdiero, M. & Romano Carratelli, C. (1995). Effects of benzodiazepines on immunodeficiency and resistance in mice. Life Sci 57, 24132423.[CrossRef][Medline]
    • George, A. M., Hall, R. M. & Stokes, H. W. (1995). Multidrug resistance in Klebsiella pneumoniae: a novel gene, ramA, confers a multidrug resistance phenotype in Escherichia coli. Microbiology 141, 19091920.[Abstract]
    • Kern, W. V., Oethinger, M., Jellen-Ritter, A. S. & Levy, S. B. (2000). Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 44, 814820.[Abstract/Free Full Text]
    • Laschi, A., Descotes, J., Tachon, P. & Evreux, J. C. (1983). Adverse influence of diazepam upon resistance to Klebsiella pneumoniae infection in mice. Toxicol Lett 16, 281284.[Medline]
    • Martínez-Martínez, L., García, I., Ballesta, S., Benedí, V. J., Hernández-Allés, S. & Pascual, A. (1998). Energy-dependent accumulation of fluoroquinolones in quinolone-resistant Klebsiella pneumoniae strains. Antimicrob Agents Chemother 42, 18501852.[Abstract/Free Full Text]
    • Martínez-Martínez, L., Pascual, A., Conejo, M. C., García, I., Joyanes, P., Doménech-Sánchez, A. & Benedí, V. J. (2002). Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum ß-lactamase production. Antimicrob Agents Chemother 46, 39263932.[Abstract/Free Full Text]
    • Mortimer, P. G. & Piddock, L. J. (1993). The accumulation of five antibacterial agents in porin-deficient mutants of Escherichia coli. J Antimicrob Chemother 32, 195213.
    • NCCLS, (2003a). Methods for dilution susceptibility for bacteria that grow aerobically; approved standard 6th edn. M07-A6. Wayne, PA: National Committee for Clinical Laboratory Standards.
    • NCCLS, (2003b). Performance standards for antimicrobial disk susceptibility tests; approved standard 8th edn. M02-A8. Wayne, PA: National Committee for Clinical Laboratory Standards.
    • Oethinger, M., Kern, W. V., Jellen-Ritter, A. S., McMurry, L. M. & Levy, S. B. (2000). Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother 44, 1013.[Abstract/Free Full Text]
    • Schneiders, T., Amyes, S. G. B. & Levy, S. B. (2003). Role of AcrR and RamA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore. Antimicrob Agents Chemother 47, 28312837.[Abstract/Free Full Text]
    • Tavío, M. M., Vila, J., Ruiz, J., Ruiz, J., Martín-Sánchez, A. M. & Jiménez de Anta, M. T. (1999). Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates. J Antimicrob Chemother 44, 735742.[Abstract/Free Full Text]